Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study

Etienne Ghrenassia, Djamel Mokart, Julien Mayaux, Alexandre Demoule, Imène Rezine, Lionel Kerhuel, Laure Calvet, Audrey de Jong, Elie Azoulay, Michael Darmon

To cite this version:
Etienne Ghrenassia, Djamel Mokart, Julien Mayaux, Alexandre Demoule, Imène Rezine, et al.. Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study. Annals of Intensive Care, SpringerOpen, 2019, 9 (1), pp.62. 10.1186/s13613-019-0539-2 . hal-02148778

HAL Id: hal-02148778
https://hal.archives-ouvertes.fr/hal-02148778
Submitted on 29 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study

Etienne Ghrenassia1,2,3 Djamel Mokart4, Julien Mayaux5, Alexandre Demoule3,5, Imène Rezine1, Lionel Kerhuel1,2, Laure Calvet1, Audrey De Jong1,6, Elie Azoulay1,2 and Michael Darmon1,2,7,8*

Abstract

Background: Immunocompromised critically ill patients constitute a population with the high risk of candidemia. This retrospective study aimed to assess the outcome of immunocompromised critically ill patients with candidemia. Secondary objectives were to describe clinical phenotypes of these patients, Candida ecology, and factors associated with mortality.

Results: Overall, 121 patients were included in this study. Median delay from candidemia to first antifungal therapy was 3 days, in line with the observed delay of blood culture positivity. Candida albicans was the main Candida specie identified (54%), and susceptibility of Candida to fluconazole and echinocandins was of, respectively, 70% and 92%. Hospital mortality was of 60%. After adjustment for confounders, severity as assessed by the need for vasopressors (HR 1.8, CI95% 1.1–3.1), need for mechanical ventilation (HR 2.0, CI95% 1.1–3.8) and allogeneic stem cell transplantation (HR 2.5, CI95% 1.1–6.0) were independently associated with poor outcome. Candida specie, susceptibility and treatment strategies were not associated with outcome.

Conclusions: Candidemia in immunocompromised critically ill patients is associated with a grim outcome. Despite the high prevalence of Candida non-albicans species, neither C. species nor its susceptibility was associated with outcome. Conversely, severity and preexisting allogeneic stem cell transplantation were independently associated with poor outcome. Despite antifungal prophylaxis and use of preemptive antifungal therapy in neutropenic patients, antifungal therapy was initiated three days after symptoms onset suggesting needs for specific strategies aiming to reduce this delay.

Keywords: Candida, Hematological malignancy, Tumor, Solid, Immune defect, Intensive care unit, Shock

Background

Candidemia represents 10% of nosocomial infections in hospitalized patients and is associated with mortality described to be as high as 40% [1–4]. Underlying immune defect, solid or hematological malignancy, may predispose to candidemia which develops during the clinical course of these conditions in 1.8% of cases [5].

Despite being widely studied, several areas of uncertainty remain. First, diagnosis of candidemia is often delayed as consequences of time required to obtain blood cultures positivity. Although several studies suggested benefit of early initiation of antifungal therapy on patients survival [6–8], evidence supporting benefits of preemptive treatment in high-risk critically ill patients is lacking [9, 10]. Antifungal resistance among documented Candida species is growing, and resistance to fluconazole and echinocandins has been described in 20% and 6.5% of Candida, respectively [4]. Last, patients’ severity and comorbidities, such as immunosuppression, are known risk factor for candidemia [11] which may participate in the observed grim prognosis of candidemia.

*Correspondence: michael.darmon@aphp.fr
1 Medical ICU, Saint Louis Hospital, Paris, France
Half of the patients with candidemia are critically ill \cite{1, 4}, mortality in patients with hemodynamic instability reaching 70\% \cite{7}. Underlying malignancy, either hematological or solid tumors, is frequently associated with candidemia, half of the patients with candidemia having underlying malignancy \cite{4}. These patients may have specific risk factors for candidemia such as catheter or neutropenia, risk factors for fluconazole-resistant species such as prophylaxis, or specific acute condition such as typhlitis \cite{12}. Nonetheless, immunocompromised critically ill patients with candidemia have been poorly described except in specific subgroups such as HIV infected patients \cite{12} or organ transplant recipients \cite{13}.

The primary objective of this study was to assess outcome of immunocompromised critically ill patients with candidemia. Our secondary objectives were to describe clinical features of these patients and fungal ecology and to identify prognostic factors in this setting.

**Methods**

**Study population**

This study is a retrospective multicenter observational study, in three ICUs located in two university hospitals (Saint-Louis and Pitié-Salpêtrière Hospitals, Paris, France) and a comprehensive cancer center (Paoli-Calmettes Institute, Marseille, France). Adult patients (age > 18 years) admitted in participating centers between January 2002 and December 2017 and who developed a candidemia 72 h before ICU admission or during ICU stay were included. Patients for whom HIV infection or solid organ transplantation was the only identified immune defect were excluded. Patients with invasive candidiasis without candidemia were also excluded.

This study was approved by the French Intensive Care Society ethics committee (CE-SRLF-18-06). Need for informed consent was waived as regard to the study observational design and in accordance with the French law. Patients alive at time of the analysis were, however, informed, and none refused to participate. This study was conducted in accordance with the principles of the Declaration of Helsinki.

**Protocol and definitions**

Patients were identified retrospectively through ICUs diagnostic files (Fig. 1).

Considering immune defect, this study intends to study patients with hematological malignancy, solid tumors or immunosuppressive drug for underlying autoimmune disease or vasculitis. Patients with solid organ transplantation or HIV as sole source of immune defect were excluded.

*Candida* colonization was defined as identification of *Candida* in at least one site including skin, urines, lung, mouth or on rectal swab.

Onset of candidemia was defined as the delay between blood sample leading to candidemia identification and antifungal therapy initiation.

Preemptive antifungal therapy was defined as antifungal therapy initiated the day of blood sampling.

A dedicated form was used to report:

1. Demographic data such as age, sex, type of immunosuppression; identified risk factors for candidemia as antifungal prophylaxis, recent abdominal surgery, recent renal replacement therapy, parenteral nutrition, presence of arterial or central venous catheter \cite{14}; intensive care unit features as SOFA at day 1, need for vasopressors and for mechanical ventilation and renal replacement therapy;
2. Candidemia features as day of first and last positive blood culture, delay of positivity, *Candida* species, fluconazole and echinocandins susceptibility based on EUCAST 2017 breakpoints \cite{15}, first and last line treatment, time to treatment introduction, time to catheter ablation, secondary localizations and delay between onset of candidemia and treatment initiation;
3. Outcomes as intensive care unit mortality, hospitalization mortality, mortality on the last follow-up.

**Statistical analysis**

We first performed a descriptive analysis in order to identify global characteristics of included patients. Data are reported as median and interquartile range or number (\%).

Factors associated with hospital mortality were identified using univariate analysis. Chi-square test or Fisher’s exact test, as appropriate, was used for categorical variables. Mann–Whitney or Wilcoxon rank-sum tests, as appropriate, were used for continuous variables. A conditional Cox model was used to identify factors independently associated with hospital mortality. Variables yielding *p* values less than 0.2 in the univariate analysis or considered clinically relevant were entered in a backward stepwise model. Critical removal *p* value was of 0.1. Only 1 variable for 7 events was included in the model in order to avoid any risk of overfitting. Proportional hazards assumption was confirmed by checking scaled Schönfeld residuals against time and correlations between covariates were searched for. Last, we planned previous the analysis to force in the final model, should these variables not be selected *Candida* species (C. albicans vs. C. non-albicans) and to force treatment strategy (echinocandin
as first-line therapy). As a post hoc analysis, ICU admission year (per quartile of ICU admission year) was forced in the final model.

Survival was plotted using Kaplan–Meier curves, and differences were assessed using log-rank test.

Last, in a way to assess the influence of candidemia on outcome, patients of this study were compared to patients in the EFRAIM dataset [16], after exclusion of patients with candidemia in this later and after exclusion having as sole immune defect solid organ transplant. Raw mortality was compared; then matching was performed on relevant variables using propensity score matching, according to closest neighbor methods and aiming to a 1:1 case–control ratio. Patients with and without candidemia were compared before and after matching according to standardized mean difference. Unadjusted mortality before matching, after matching and after matching and after adjustment for SOFA score was performed using Kaplan–Meier curves, log-rank test and Cox model.

All tests were two-sided, and p values less than 0.05 were considered statistically significant.

All statistical tests were performed using R software (https://www.r-project.org/); ‘matchIt’ and ‘survival’ package.
Results
Patients’ characteristics
Overall, among the 31,792 patients admitted in the participating ICUs during the study period, 219 developed a candidemia (0.7%). Overall, 121 had an underlying immune defect as defined by our protocol and were included (Fig. 1).

Main patients’ characteristics are reported in Table 1 and Additional file 1: Table S1.

Median age was 60 years (IQR 49–66), and 74 (61%) were of male gender. Two-third of the patients had hematological malignancy, lymphoma (37%) and acute leukemia (21%) being main underlying diseases. Respectively, 10% and 7% of included patients were autologous or allogenic stem cell transplant recipients. Among solid tumors, breast (25%), lung (11%) and gynecological (11%) cancers were the most prominent.

Most of the patients had one or several risk factors for candidemia including Candida colonization (81%), presence of central venous catheter (94%), need for renal replacement therapy (38%), parenteral nutrition (30%) or recent abdominal surgery (12%). Similarly, several

| Table 1  Hospital mortality risk factors (number (%)) or median (IQR) |
|------------------|-----------------|-----------------|-----------------|-----------------|
| Clinical features | Total $N=121$ | Dead $N=73$ | Alive $N=48$ | $p$ value |
| Female gender | 47 (39%) | 24 (33%) | 23 (48%) | 0.13 |
| Age | 60 (49–66) | 60 (49–65) | 61 (52–68) | 0.3 |
| Median year of ICU admission (IQR) | 2013 (2010–2015) | 2013 (2010–2016) | 2013 (2010–2015) | 0.86 |
| Underlying immunosuppression | | | | |
| Solid tumors | 36 (30%) | 19 (26%) | 17 (35%) | 0.31 |
| Hematological malignancy | 81 (67%) | 52 (71%) | 29 (60%) | 0.24 |
| Allogenic SCT | 8 (7%) | 7 (10%) | 1 (2%) | 0.14 |
| Acute myeloid leukemia | 17 (14%) | 10 (14%) | 7 (15%) | 1 |
| Acute lymphoid leukemia | 9 (7%) | 7 (10%) | 2 (4%) | 0.32 |
| Lymphoma | 45 (37%) | 29 (40%) | 16 (33%) | 0.56 |
| Myelodysplasia | 6 (5%) | 4 (5.5%) | 2 (4%) | 1 |
| Autoimmune disease | 13 (11%) | 11 (15%) | 21 (46%) | 0.71 |
| HIV infection | 19 (16%) | 11 (15%) | 8 (17%) | 0.80 |
| Neutropenia | 58 (49%) | 37 (51%) | 21 (46%) | 0.005 |
| ICU features | | | | |
| SOFA score | 10 (6–15) | 12 (8–16) | 8 (5–14) | 0.011 |
| Surgical patient | 25 (21%) | 15 (20%) | 10 (21%) | 1 |
| Renal replacement therapy | 71 (61%) | 50 (68.5%) | 22 (46%) | 0.005 |
| Invasive mechanical ventilation | 91 (75%) | 61 (85%) | 31 (65%) | 0.015 |
| Vasopressors | 66 (54.5%) | 45 (62%) | 21 (44%) | 0.06 |
| Candidemia features | | | | |
| Antifungal prophylaxis | 20 (17%) | 16 (22%) | 4 (8%) | 0.08 |
| ICU acquired candidemia | 70 (58%) | 44 (63%) | 26 (54%) | 0.5 |
| Candida albicans | 65 (54%) | 39 (53%) | 26 (54%) | 1 |
| Candida glabrata | 23 (19%) | 13 (18%) | 10 (21%) | 0.81 |
| Candida tropicalis | 13 (11%) | 9 (12%) | 4 (8%) | 0.56 |
| Candida krusei | 9 (7%) | 7 (10%) | 2 (4%) | 0.32 |
| Candida parapsilosis | 9 (7%) | 5 (7%) | 4 (8%) | 0.74 |
| Fluconazole susceptibility | 61 (70%) | 35 (71%) | 27 (59%) | 1 |
| Echinocandins susceptibility | 73 (92%) | 39 (99%) | 34 (97%) | 0.22 |
| Adequacy of first AF therapy | 78 (90%) | 43 (86%) | 36 (94%) | 0.29 |
| CVC removed | 103 (97%) | 61 (98%) | 42 (95.5%) | 0.57 |
| Days to first AF therapy (IQR) | 3 (1–3) | 3 (1–3) | 3 (1–3) | 0.45 |
| Preemptive antifungal therapy | 27 (22%) | 16 (22%) | 11 (23%) | 1.00 |

Adequacy is based on antifungal susceptibility of involved Candida based on MIC
ICU intensive care unit, IQR interquartile range, SCT stem cell transplantation, AF antifungal therapy, CVC central venous catheter
immune defects were frequently associated including HIV infection (16%), known hypogammaglobulinemia (10%) and neutropenia (49%). Interaction between the main risk factors is reported in Additional file 1: Figure S1.

At ICU admission, severity as assessed by SOFA score was 10 (6–15). The vast majority of patients had a medical condition, and 25 (21%) were admitted for a surgical emergency. Half of patients (54.5%) required vasopressors at ICU admission.

During ICU stay, 91 (75%) patients required invasive mechanical ventilation, 71 (61%) required renal replacement therapy, and 91 (75%) required vasopressors.

**Candidemia characteristics**

Half of the patients (42%) were admitted in ICU after onset of the candidemia, the remaining patients having ICU acquired candidemia (Additional file 1: Table S2). Proportion of patients with breakthrough candidemia (under antifungal prophylaxis) was 16.5%. Main characteristics of candidemia are reported in Additional file 1: Table S1. *Candida albicans* (54%) was the predominant specie, followed by *C. glabrata* (19%), *C. tropicalis* (11%), *C. parapsilosis* (7%) and *C. krusei* (7%). One-third of identified *Candida* was resistant to fluconazole (30%) and 8% to echinocandins.

The median delay to blood culture positivity was 3 days (range 1–6). Enterocolitis was the most frequent infection site (56%). Among the 99 cultured catheters, 18 (18%) were colonized or infected. Secondary localizations included endophthalmitis (10%), cutaneous lesions and thrombosis (8% each). Despite being searched for, no patient developed osteo-articular infection or endocarditis. Chronic disseminated candidiasis with hepatosplenic lesions was described in two patients (2%).

First-line antifungal therapy was adapted to documented specie in the vast majority of the patients (90%), and central venous catheter was nearly systematically removed (97%) within 3 days (IQR 2–4). Median delay from onset of candidemia to first antifungal therapy was 3 days (IQR 1–3).

**Outcome and factors associated with hospital mortality**

ICU mortality was of 52%, and hospital mortality was of 60% (Fig. 2). Before adjustment, patients’ severity as assessed by organ support or severity score was the main variables associated with hospital mortality (Table 1).

After adjustment for confounders, allogeneic stem cell transplantation, vasopressors and invasive mechanical ventilation were independently associated with hospital mortality. *Candida* species were not significantly associated with outcome when forced in the final model and did not change this later (Table 2, Figs. 3, 4). Last, when forced in the Cox model, neither treatment strategies (echinocandin as first-line therapy) nor ICU admission years per quartile were selected or modified the model.

**Outcome in patients with and without candidemia**

In a way to further explore the influence of candidemia on outcome, our study population was compared to a control group without candidemia and described elsewhere [16]. Main characteristics of patients with and without candidemia are reported in Additional file 1: Table S3. Distribution of propensity score and patients characteristic before and after matching, and changes in mean standardized difference and patients’ characteristics after matching are reported in Additional file 1: Figure S2, Figure S3, Figure S4 and Table S4. No influence of candidemia on mortality was noted before matching (Additional file 1: Figure S5), after matching (Additional file 1: Figure S6) or after adjustment for SOFA score at ICU admission (HR 0.78, 95%CI 0.58–1.09).

**Discussion**

This study is the first to describe clinical features and outcome of this specific population. Hospital mortality in this setting was 60%. Patients’ severity as assessed by organ support and allogeneic stem cell transplantation were independently associated with hospital mortality. Conversely, *Candida* species, susceptibility to antifungal therapies or neutropenia, had no influence on outcome.

The observed poor prognosis is concordant with previous studies in this field. Hence, overall mortality after candidemia has been reported to be up to 40% in the general population [1–4], rising to 50% in critically ill patients [1, 4] and 70% in patients with septic shock [7]. Mortality of onco-hematological patients with candidemia was reported to be of 40% [4, 17, 18]. Recently, Lortholary et al. [4] reported in a large prospective cohort of candidemia, a mortality of 50% for onco-hematological patients admitted in ICU with candidemia. Our data are in line with these reports, suggesting a high mortality associated with both underlying immune defect and underlying comorbidities.

Interestingly, in this study, most of the variables associated with outcome were surrogate of patients’ severity. These data are concordant with previous studies that reported higher mortality of critically ill patients with candidemia [1, 4]. In this line, Kollef et al. [7], reported a 69% mortality in patients with septic shock and candidemia. Although neutropenia has been associated with poor outcome in the general population of patients with candidemia [8], we were unable to detect such an effect in this study. The only exception is the peculiar population of allogeneic stem cell transplant recipients. These data are concordant with the poor prognosis of critically
ill allogeneic stem cell transplant recipients, in whom a mortality of 51% was described, rising to 71% when mechanical ventilation was needed [19]. In this cohort, allogeneic stem cell transplant recipients with candidemia had a hospital mortality of 88%. This high mortality may reflect cumulative impact of mortality risk in this subgroup, direct influence of candidemia and the fact that candidemia may be a surrogate marker of severity or underlying immune defect in these patients [20, 21]. This later is further underlined by the lack of influence of candidemia on outcome after adjustment for confounders and when compared to a control group of patients without candidemia [16].

Last, several findings specific to candidemia and its management are to be noted. First, Candida specie and susceptibility had no influence on outcome. Some of the previous studies reported Candida specie, namely C. glabrata or C. parapsilosis to be associated with better prognosis [4, 8, 22]. This association is, however, inconstantly reported in the literature [4, 5], and our results do not support such association. Our study may, however, lack statistical power to detect such an effect. Similarly, we were unable to detect the influence of management strategies on outcome. Neither initial therapy nor catheter withdrawal was associated with outcome while having been demonstrated factors associated with survival for patients with candidemia by previous studies [7, 8, 23], and being recommended by guidelines [6]. This may be explained by the homogenous management

Table 2. Mortality associated factors (multivariate analysis. Cox model)

| Mortality associated factors | HR   | CI95%   | p value |
|-----------------------------|------|--------|---------|
| Candida albicans            | 0.98 | 0.60–1.6 | 0.93    |
| Invasive mechanical ventilation | 1.98 | 1.03–3.81 | 0.04    |
| Vasopressors                | 1.85 | 1.12–3.07 | 0.02    |
| Allogenic SCT               | 2.51 | 1.05–5.99 | 0.04    |

SCT stem cell transplantation, HR hazard ratio, CI95% confidence interval 95%
strategies in this study leading to high rate of catheter removal and systemic initiation of antifungal treatment the day of *Candida* identification. Nonetheless, the delay from onset of symptoms to antifungal therapy or catheter removal remained unacceptably long with a median of 3 days, reflecting time to culture positivity. Hence, despite rate of antifungal prophylaxis in this population (18%) and preemptive therapies, antifungal therapy remains dictated in this setting by culture positivity. This may reflect either a lack of clinical vignette specific enough to lead to adequate preemptive therapy initiation or failure to identify these vignettes. Development and validation of strategy that may allow reduction of this delay may be required. In this line, extension and validation of preemptive strategy in immunocompromised patients, excluded from recent trials [9, 10], validation of biomarkers driven strategies in this setting might deserve to be evaluated.

Our study has several limitations. First, the observational design and lack of a control group preclude any causality inference in this setting. In addition, this study was performed in only three centers, with high volume and experience of immunocompromised patients. This could explain the homogeneity in terms of patients cares and might constitute a selection bias. In this line, rate of hematological malignancies was high, and over-represented, in line with case mix in participating centers. Whether this may partly explain the lack of influence of underlying disease may deserve to be assessed by additional studies. In this line, the study period extends over a decade and changes in practices may have influenced our findings. We described two different groups of patients with candidemia, namely patients with ICU acquired candidemia and patient admitted in ICU for candidemia. If mixing these two
Conclusion

Our results confirm the high mortality of candidemia in immunocompromised critically ill patients despite adequate first-line therapy and high adherence to recommendation in most patients. In this setting, initial severity and underlying allogenic stem cell transplantation are main factors associated with outcome, while Candida specie and susceptibility do not appear to be associated with outcome. Last, despite antifungal prophylaxis and use of preemptive antifungal therapy in neutropenic patients, antifungal therapy proves to be initiated 3 days after onset of candidemia, suggesting need for better risk stratification and validation of dedicated preemptive strategies.
Abbreviations
Ct: confidence interval; ICU: intensive care unit; IQR: interquartile range; OR: odds ratio; SOFA: sepsis-related organ failure assessment; EUCAST: European Committee on Antimicrobial Susceptibility Testing; SCT: stem cell transplantation.

Acknowledgements
Not applicable.

Authors' contributions
EG and EA conceived the study and participated in study design and coordination, acquisition of data, statistical analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript. DM, JM, AD, IR, LC and AD participated in acquisition of data, interpretation of data, drafting of the manuscript and critical revision of the manuscript. MD participated in study design and coordination, acquisition of data, statistical analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript. MD had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MD affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as registered have been explained. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethical approval
This study was approved by the French Intensive Care Society ethics committee (CE-SRLF-18-06) and “Commission Nationale Informatique et Liberté” (CNIL) (DR 218-207). Need for informed consent was waived as regard to the study observational design and in accordance with the French law. Patients alive at time of the analysis were, however, informed, and none refuse to participate. This study was conducted in accordance with the principles of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
E Azoulay reports having received fees for lectures from Alexion, Gilead, and Baxter. His institution and research group have received support from Fisher & Paykelle, Pfizer, Ablyxyn, MSD and Jazz Pharma. M. Damron reports having received research support from MSD and from ASTUTE medical, speaker fees from MSD, Astellas and Bristol-Myers-Squibb, support to organize educational meeting from MSD, Astellas and Jazz Pharma and having participated to an advisory board from SANOFI-AVENTIS. A. De Jong reports personal fees from Baxter and Medtronic-Covidien and travel reimbursements from Fresenius-Kabi, MSD France, Astellas, Pfizer and Fisher Paykel. Dr. Demoule reports non-financial support from Medtronic, personal fees and non-financial support from Philips, grants and personal fees from Resmed, personal fees from Baxter, personal fees from Hamilton, non-financial support from Fisher & Paykel, grants from French Ministry of Health, outside the submitted work. Other authors declare having no competing interest to declare.

Author details
1 Medical ICU, Saint Louis Hospital, Paris, France. 2 Paris Diderot University, Paris, France. 3 Sorbonne University, Paris, France. 4 ICU, Paoli-Calmettes Institute, Marseille, France. 5 Medical ICU, Pitié-Salpêtrière Hospital, Paris, France. 6 Département d'anesthésie-réanimation Saint-Eloi, PhyMedExp, INSERM, CNRS, CHU de Montpellier, Université de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier Cedex, France. 7 ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistic Sorbonne Paris Cité, CRESS), INSERM, Paris, France. 8 Public Health Department, Robert Debré University Hospital, AP-HP, Paris, France.

References
1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;39(3):309–17.
2. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;37(5):634–43.
3. Pfäfflé M, Neofytos D, Diekema D, Aziz N, Meier-Kriesche H-U, Quan S-P, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective AntiFungal Therapy (PATH) Alliance registry. 2004–2008. Diagn Microbiol Infect Dis. 2012;74(4):323–31.
4. Lortholary O, Renaudat C, Sibton K, Desnos-Ollivier M, Bretagne S, Dromer F, et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med. 2017;43(5):652–62.
5. Comely OA, Gachot B, Akan H, Bassetti M, Usun O, Kibbler C, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC). 65031). Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61(3):324–31.
6. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62(4):e1–50.
7. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54(12):1739–46.
8. Andes DR, Safram N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54(8):1110–22.
9. Timsit J-F, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, et al. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA. 2016;316(15):1555–64.
10. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58(9):1219–26.

11. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(2):177–86.

12. Lorholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdag L, Basseti M, et al. ESCMID® guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(Suppl 7):68–77.

13. Basseti M, Peghin M, Carnelutti A, Righi E, Merelli M, Ansaldi F, et al. Invasive Candida infections in liver transplant recipients: clinical features and risk factors for mortality. Transplant Direct. 2017;3(5):e156.

14. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51.

15. EUCAST: Clinical breakpoints [Internet]. [cited 2018 Jan 9]. http://www.eucast.org/clinical_breakpoints/.

16. Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efrain multinational prospective cohort study. Intensive Care Med. 2017;43(12):1808–19.

17. Ganaletou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgaris M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies.